{"id":69,"count":0,"description":"<h2>Best Practice Recommendations <\/h2>\r\nFor Immune Globulin (IG) stewardship in Ontario, it is crucial to follow these key recommendations when providing patient care:\r\n\r\n<div style=\"border: 1px solid #ccc; padding: 15px; background-color: #f9f9f9; border-radius: 5px; margin: 20px 0;\">\r\n<p>IG is only prescribed where there is evidence to support use, and<\/p>\r\n<ol>\r\n<li>Alternative therapies have failed or are not feasible \/ available<\/li>\r\n<li>IG dose is prescribed as per adjusted body weight calculator criteria<\/li>\r\n<li>Use should be discontinued if benefit is not demonstrated<\/li>\r\n<li>For continued use (i.e., maintenance therapy) the evaluation of clinical effectiveness must:\r\n<ul>\r\n<li>Be performed 6 months after initiation of therapy and at minimum annually thereafter<\/li>\r\n<li>Include adjustment to the lowest effective dose and\/or greatest treatment interval<\/li>\r\n<li>Consider trials of alternative therapies where appropriate<\/li>\r\n<\/ul>\r\n<\/li>\r\n<\/ol>\r\n<\/div>\r\n\r\nORBCoN is funded by the Ontario Ministry of Health to develop, distribute, promote and educate users on blood utilization management, including IG utilization best practices. The list of medical conditions found on this page is per version 5.0 of the Ontario Immune Globulin Utilization Management (IGUM) document. (The full version document can be downloaded from the link on the right side of this page) The additional indications incorporated within version (5.0) are largely adopted with permission from the <a href=\"https:\/\/ihe.ca\/resource-library\/?_doc_tags=immune-globulin\" target=\"_blank\" >Criteria for the Clinical Use of Immune Globulin<\/a> document. This document was the output of the Prairie Collaborative Immune Globulin Utilization Management Framework Project, a collaboration of an Inter-Provincial Medical Expert Committee, the Institute of Health Economics of Alberta, the Alberta Ministry of Health, Shared Health Manitoba, and the Saskatchewan Ministry of Health. \r\n\r\nThis summary of medical conditions and information on IG utilization has been prepared specifically for use in Ontario, based on the input from the Ontario IG Advisory Panel. There may be new evidence to support IG use in other medical conditions since publication of the Prairie Collaborative document that has not been included in the Ontario IGUM version (5.0) document. New evidence will be evaluated in the future comprehensive revision of the Criteria for the Clinical Use of Immune Globulin document. \r\n\r\nThis information is intended as supportive for prescribers of IG seeking clarification on the common and clinically appropriate uses of IG. Unless specifically indicated, use applies to both Intravenous (IVIG) and Subcutaneous (SCIG) forms of IG. The use of SCIG should be evaluated based on patient medical condition as well as ability to tolerate and self administer. \r\n\r\n<a href=\"https:\/\/transfusionontario.org\/en\/category\/ivig-scig\/dosing-using-adjusted-body-weight\/\" target=\"_blank\" style=\"color: #fff; background-color: #083459; padding: 0.25rem 0.5rem; font-size: 0.875rem; line-height: 1.5; border-radius: 0; text-decoration: none; display: inline-block;\">The Dose Calculator<\/a>\r\n\r\n<a href=\"https:\/\/transfusionontario.org\/en\/category\/ivig-scig\/ordering-ig-in-ontario\/\" target=\"_blank\" style=\"color: #fff; background-color: #083459; padding: 0.25rem 0.5rem; font-size: 0.875rem; line-height: 1.5; border-radius: 0; text-decoration: none; display: inline-block;\">The MOH request forms for IVIG (neurology and non-neurology) and SCIG<\/a>\r\n\r\n<a href=\"https:\/\/transfusionontario.org\/wp-content\/uploads\/2025\/01\/Communication-Updates-at-a-Glance_Final.pdf\" target=\"_blank\" style=\"color: #fff; background-color: #083459; padding: 0.25rem 0.5rem; font-size: 0.875rem; line-height: 1.5; border-radius: 0; text-decoration: none; display: inline-block;\">Updates at a Glance<\/a","link":"https:\/\/transfusionontario.org\/en\/category\/ivig-scig\/utilization-management-guidelines\/","name":"Utilization Management Guidelines","slug":"utilization-management-guidelines","taxonomy":"category","parent":27,"meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/categories\/69","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/categories"}],"about":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/taxonomies\/category"}],"up":[{"embeddable":true,"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/categories\/27"}],"wp:post_type":[{"href":"https:\/\/transfusionontario.org\/en\/wp-json\/wp\/v2\/posts?categories=69"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}